Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 61
Filter
1.
Clin Exp Med ; 3(2): 119-23, 2003 Sep.
Article in English | MEDLINE | ID: mdl-14598187

ABSTRACT

Patients with normal or borderline sweat tests present a diagnostic challenge. In spite of the availability of genetic analysis and measurement of nasal potential difference, there is still uncertainty in diagnosing cystic fibrosis in some patients. CA 19-9 is a tumor-associated antigen whose levels were previously found to be elevated in some cystic fibrosis patients. We investigated whether serum CA 19-9 levels can contribute to establishing the diagnosis of cystic fibrosis in patients with a borderline sweat test, and evaluated the influence of different clinical variables on CA 19-9 levels. Serum CA 19-9 levels were measured in 82 cystic fibrosis patients grouped according to their genotype and in 38 healthy individuals. Group A included 50 patients who carried two mutations previously found to be associated with a pathological sweat test and pancreatic insufficiency (DeltaF508, W1282X, G542X, N1303K, and S549R). Group B included 13 compound heterozygote cystic fibrosis patients who carried one mutation known to cause mild disease with a borderline or normal sweat test and pancreatic sufficiency (3849+10kb C-->T, 5T). Group C included 38 normal controls. Nineteen cystic fibrosis patients carried at least one unidentified mutation. An association between CA 19-9 levels and age, pulmonary function, pancreatic status, sweat chloride, previous pancreatitis, serum lipase, meconium ileus, distal intestinal obstruction, liver disease, and diabetes was investigated. The distribution of CA 19-9 levels was significantly different between the three groups ( p<0.01); high CA 19-9 levels were found in 60% (30/50) of group Apatients and in 46.6% (6/13) of group B patients, but in only 5.2% (2/38) of the controls. CA 19-9 levels were inversely related to forced expiratory volume in 1 s, while no association was found with the other clinical parameters examined. Our findings suggest that the serum CA 19-9 in cystic fibrosis patients originates in the respiratory system, and has a useful ancillary role, particularly when diagnostic uncertainty exists. Hence, the diagnosis of cystic fibrosis should be considered in patients with borderline sweat tests and high CA 19-9 levels, but normal levels do not exclude cystic fibrosis.


Subject(s)
CA-19-9 Antigen/blood , Cystic Fibrosis/diagnosis , Electrolytes/analysis , Sweat/chemistry , Adolescent , Adult , Child , Cystic Fibrosis/blood , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Cystic Fibrosis Transmembrane Conductance Regulator/physiology , Humans , Mutation
2.
Pediatr Transplant ; 5(5): 339-42, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11560752

ABSTRACT

Lung transplantation (Tx) is an optional treatment for cystic fibrosis (CF) patients with end-stage lung disease. The decision to place a patient on the Tx waiting list is frequently complex, difficult, and controversial. This study evaluated the current criteria for lung Tx and assessed additional parameters that may identify CF patients at high risk of death. Data were extracted from the medical records of 392 CF patients. Forty of these patients had a forced expiratory volume in 1 s (FEV(1)) less than 30% predicted, and nine of these 40 patients were transplanted. A comparison was performed between the survival of those transplanted (n = 9) and those not transplanted (n = 31), by means of Kaplan-Meier survival curves. The influence on survival of age, gender, nutritional status, sputum aspergillus, diabetes mellitus, recurrent hemoptysis, oxygen use, and the decline rate of FEV(1), were investigated by means of univariate and multivariate analyses. The rate of decline of FEV(1) was evaluated employing the linear regression model. CF patients with a FEV(1)< 30% and who did not receive a lung transplant had survived longer than CF patients who did receive a lung transplant (median survival 7.33 vs. 3.49 yr, 5-yr survival 73% vs. 29%). Two factors--rate of decline in FEV(1) values and age < 15 yr--were found to influence the mortality rate, while the other parameters examined did not. Our results indicate that the current criterion of FEV(1)< 30% predicted, alone is not sufficiently sensitive to predict the mortality rate in CF patients and time of referral for Tx, as many of these patients survive for long periods of time. Additional criteria to FEV(1)< 30%, should include rapidly declining FEV(1) values and age < 15 yr.


Subject(s)
Cystic Fibrosis/mortality , Cystic Fibrosis/surgery , Lung Transplantation , Patient Selection , Adolescent , Cystic Fibrosis/physiopathology , Female , Forced Expiratory Volume , Humans , Linear Models , Male , Prognosis , Proportional Hazards Models , Referral and Consultation , Survival Analysis
3.
Int J Clin Lab Res ; 29(3): 114-6, 1999.
Article in English | MEDLINE | ID: mdl-10592108

ABSTRACT

The determination of endocrine and exocrine pancreatic function in cystic fibrosis patients is clinically important. Recently, a new non-invasive test, in which pancreatic stimulation by a Lundh meal is followed by sequential serum lipase measurements, was found to be a good indicator of exocrine pancreatic status. Since the Lundh meal also contains glucose, the present study assessed whether it also might be suitable for evaluation of the pancreatic endocrine axis. After an overnight fast, 10 healthy non-diabetic subjects and 14 cystic fibrosis patients ingested a Lundh meal. Glucose, insulin, and C peptide levels were measured at various time intervals following the meal. For purposes of comparison, the oral glucose tolerance test was also performed on the cystic fibrosis patients. All healthy subjects demonstrated an increase in glucose levels post Lundh meal, peaking at 45 min (mean 140+/-21 mg/dl) and then gradually declining and reaching the normal range at 120 min. Concordant peaks of insulin (46.3+/-20 IU/ml) and C peptide (5.8+/-1. 5 ng/ml) levels were noted at 60 min. All 14 cystic fibrosis patients had normal basal glucose levels: in 8, the pattern of glucose, insulin, and C peptide post Lundh meal was similar to that of the healthy controls. These 8 patients also had a normal oral glucose tolerance test, and their hemoglobin A(1C) levels were within the normal range. The other 6 cystic fibrosis patients demonstrated glucose levels above 200 mg/dl 30-60 min post Lundh meal, and all also had an impaired oral glucose tolerance test. Of these 6, 4 had high levels of hemoglobin A(1C). This study demonstrates that the Lundh meal challenges the endocrine pancreas as well as the oral glucose tolerance test. Thus, determination of both exocrine and endocrine pancreatic status can be achieved by a single non-invasive test.


Subject(s)
Cystic Fibrosis/diagnosis , Cystic Fibrosis/physiopathology , Islets of Langerhans/physiopathology , Pancreas/physiopathology , Pancreatic Function Tests/methods , Adolescent , Adult , Blood Glucose/metabolism , C-Peptide/blood , Case-Control Studies , Cystic Fibrosis/blood , Diet , Evaluation Studies as Topic , Female , Glucose Tolerance Test , Humans , Insulin/blood , Male , Time Factors
4.
Int J Clin Lab Res ; 28(4): 226-9, 1998.
Article in English | MEDLINE | ID: mdl-9879495

ABSTRACT

Determination of pancreatic function is essential in cystic fibrosis. The most-reliable method is by measuring pancreatic enzymes in the duodenum following intravenous or oral stimulation. However, this is invasive, time consuming, and expensive. Indirect tests are non-invasive but lack accuracy. This study examines a simple test which combines pancreatic stimulation by Lundh meal and sequential serum lipase measurements. The test was performed on three groups: group A, 36 cystic fibrosis patients carrying two mutations associated with severe disease and pancreatic insufficiency (delta F508, W1282X, G542X, N1303K, S549R); group B, 8 compound heterozygote cystic fibrosis patients carrying one mutation causing mild disease with pancreatic sufficiency (3849 + 10 kb C-->T); group C, 17 healthy individuals. Basal lipase levels were 2-16.5, 16.4-73, and 8.5-27.8 U/l in groups A, B, and C, respectively, with some overlapping between groups. There were three patterns of lipase activity (1) consistently low levels (group A) suggested a severely affected insufficient pancreas; (2) normal basal levels followed by a linear rise peaking 30 min after the meal (found in 16 of 17 healthy individuals and 3 patients of group B) reflecting an unaffected sufficient pancreas; (3) elevated lipase levels not influenced by the meal (5 patients of group B). This reflects an ongoing destructive process in the pancreas which will eventually result in conversion from pancreatic sufficiency to pancreatic insufficiency. Hence serum lipase activity prior to and 30 min after Lundh meal is a good indicator of pancreatic status allowing categorization of cystic fibrosis patients as pancreatic insufficient, pancreatic sufficient, or pancreatic sufficient with late conversion to insufficiency.


Subject(s)
Cystic Fibrosis/diagnosis , Dietary Fats/administration & dosage , Lipase/blood , Pancreas/enzymology , Pancreatic Diseases/diagnosis , Adolescent , Adult , Child , Cystic Fibrosis/metabolism , Humans , Pancreatic Diseases/metabolism , Pancreatic Function Tests , Postprandial Period
5.
Pediatr Pulmonol ; 24(2): 134-6; discussion 159-61, 1997 Aug.
Article in English | MEDLINE | ID: mdl-9292909

ABSTRACT

The syndrome of infantile bronchiolitis in cystic fibrosis (CF) carries a high mortality. Fifteen cases of CF encountered over the past 19 years with severe bronchiolitis with onset during the first 6 months of life are described. Treatment include steroids in high doses. All patients recovered. Further progress resembled the usual natural course of CF and showed no evidence of persisting lung damage. The mechanism of this syndrome is not clear and is probably dependent on many factors involved in early lung disease in CF. The frequency of severe bronchiolitis in cystic fibrosis may not be high, but it continues to be seen in clinical practice today.


Subject(s)
Bronchiolitis/etiology , Cystic Fibrosis/complications , Cystic Fibrosis/physiopathology , Cystic Fibrosis/therapy , Female , Humans , Infant , Infant, Newborn , Male
6.
Arch Otolaryngol Head Neck Surg ; 115(7): 876-7, 1989 Jul.
Article in English | MEDLINE | ID: mdl-2660855

ABSTRACT

Tuberculosis of the middle ear is currently a rare disease. As most physicians are unfamiliar with the typical presenting features, the diagnosis is made too late, with resulting complications, such as irreversible hearing loss and facial nerve paralysis. A case report and review of the literature are presented, emphasizing that tuberculosis should be considered in the differential diagnosis of chronic ear infection.


Subject(s)
Otitis Media/etiology , Tuberculosis , Diagnosis, Differential , Hearing Loss, Conductive/etiology , Humans , Infant , Male
7.
Respiration ; 55(3): 144-51, 1989.
Article in English | MEDLINE | ID: mdl-2682864

ABSTRACT

The immediate effect of four different modes of treatment was assessed by lung function tests on 19 infants with cystic fibrosis (CF) during the first year of life. The regimens were applied in a randomized fashion and consisted of aerosol inhalation of salbutamol (n = 8; SAL), aerosol inhalation of N-acetyl cysteine (n = 5; AC), chest physiotherapy (n = 6; CPT), and combined treatment with aerosol inhalation of SAL and AC followed by CPT (n = 6; COMB). Pulmonary function was measured before and shortly after therapy with each mode of treatment. Thoracic gas volume (Vtg) and specific airway conductance (SGaw) were measured by an infant whole body plethysmograph, and forced expiratory flow at resting lung volume (VmaxFRC) was determined with a thoraco-abdominal squeeze jacket. There was no correlation between baseline lung function and changes in any parameter due to treatment. Overall group comparison showed that the combined therapy resulted in a significant improvement in lung function when compared to any of the three treatments applied separately. There was no significant change in lung volumes in any individual group, but SGaw and VmaxFRC showed a small but significant improvement following the COMB treatment when compared with AC or CPT.


Subject(s)
Cystic Fibrosis/therapy , Acetylcysteine/administration & dosage , Acetylcysteine/therapeutic use , Administration, Inhalation , Albuterol/administration & dosage , Albuterol/therapeutic use , Combined Modality Therapy , Humans , Infant , Methods , Physical Therapy Modalities , Respiratory Function Tests
8.
Thorax ; 43(7): 545-51, 1988 Jul.
Article in English | MEDLINE | ID: mdl-3212751

ABSTRACT

Lung function was measured in 28 infants with cystic fibrosis and repeated in 17 of the infants during the first year of life. Thoracic gas volume (TGV) and specific airway conductance (sGaw) were measured plethysmographically and maximum forced expiratory flow at functional residual capacity (VmaxFRC) was derived from the partial expiratory flow-volume curve. At the time of the initial evaluation respiratory function was correlated with the clinical condition of the infants but not with age. There was a good correlation between sGaw and VmaxFRC when both were expressed as percentages of the predicted normal values. On the basis of the normal range for sGaw the infants were divided into two groups. Group A (n = 9), who had normal sGaw, were younger and had a lower clinical score and normal VmaxFRC and TGV values. Group B (n = 19), who had low sGaw, had increased TGV and decreased VmaxFRC. There was no correlation with age for any measure of lung function for the population as a whole. Repeat testing was undertaken at intervals in 17 representative infants. In most of these infants the relation between sGaw and VmaxFRC was maintained; there was no evidence that VmaxFRC was affected before sGaw. There was no functional evidence that the earliest changes in cystic fibrosis occur in small airways, as reflected by changes in VmaxFRC in infancy.


Subject(s)
Cystic Fibrosis/physiopathology , Lung/physiopathology , Airway Resistance , Body Weight , Follow-Up Studies , Forced Expiratory Flow Rates , Humans , Infant , Infant, Newborn , Lung Volume Measurements
9.
Arch Dis Child ; 63(6): 592-7, 1988 Jun.
Article in English | MEDLINE | ID: mdl-3133990

ABSTRACT

The clinical response to sodium cromoglycate treatment was compared with its concentration in serum. Twenty five children with asthma entered a 10 week trial of two baseline weeks followed by eight weeks of treatment by the inhalation of 20 mg of sodium cromoglycate spincaps four times a day. Individual clinical response was determined by the differences between baseline and treatment periods of: (a) percentage of symptomless days (delta score 0); (b) diary derived daily score for four symptoms (delta DS); and (c) peak expiratory flow rate (delta PEFR). At the end of the treatment period, patients inhaled a 20 mg spincap of sodium cromoglycate and the technique of inhalation was graded. Concentrations of sodium cromoglycate in serum were measured by radioimmunoassay in samples withdrawn 5 to 120 minutes after inhalation. Delta Score 0, delta DS, and delta PEFR correlated significantly with the area under the concentration time curve. Both the area under the sodium cromoglycate concentration time curve and clinical response correlated significantly with inhalation technique score. We suggest that response of children with asthma to inhalation treatment with sodium cromoglycate is correlated to its serum concentrations.


Subject(s)
Asthma/prevention & control , Cromolyn Sodium/therapeutic use , Administration, Inhalation , Adolescent , Asthma/blood , Child , Cromolyn Sodium/administration & dosage , Cromolyn Sodium/blood , Female , Humans , Male , Prospective Studies
11.
Am J Med Genet ; 28(4): 935-47, 1987 Dec.
Article in English | MEDLINE | ID: mdl-3688032

ABSTRACT

Prenatal diagnosis of cystic fibrosis is presently based on the determination of microvillar enzyme activities in the amniotic fluid. However, there seems to be no accurate means for confirming the diagnosis of the aborted fetus. During the past year we performed pathological and histopathological examinations on 7 fetuses diagnosed in the second trimester of pregnancy to be affected by cystic fibrosis and compared them with 4 control age-matched fetuses. Glycol-methacrylate-embedded 2-3-mu thick sections of the pancreas, lungs, bronchial tree, and GI tract were stained with toluidine blue, H&E, PAS, and AB-PAS, and examined microscopically. In the controls, PAS-positive granules were dispersed throughout the cytoplasm of most pancreatic acinar and tracheal submucosal glandular cells. In the affected fetuses 2 distinct groups were identified. In one group of 4 fetuses, the pancreatic and tracheal submucosal glands were dilated and contained a weak PAS-positive material. The glandular epithelial cells had very little PAS-positive granules. In this group, the tracheal epithelium was either atrophic or metaplastic and devoid of microvilli. In the second group of 3 fetuses there was less dilation of the glands, and both pancreatic acinar cells and tracheal submucosal glandular epithelial cells contained few PAS-positive granules, which were confined mainly to a perinuclear location. The tracheal epithelial cells contained few microvilli which, when present, appeared thicker and shorter as compared to controls. We feel that histochemical evaluation of pancreatic and bronchial tissue may be of help in the pathological confirmation of cystic fibrosis in human fetuses where the results of the biochemical studies are suggestive of the disease.


Subject(s)
Cystic Fibrosis/pathology , Fetal Diseases/pathology , Prenatal Diagnosis , Cytoplasmic Granules/ultrastructure , Female , Humans , Male , Microscopy, Electron , Mucous Membrane/pathology , Muscle, Smooth/pathology , Pancreas/pathology , Pregnancy
12.
Hum Genet ; 75(1): 41-4, 1987 Jan.
Article in English | MEDLINE | ID: mdl-3026947

ABSTRACT

Vasoactive intestinal peptide (VIP) is a regulatory neuropeptide involved in a wide variety of functions, among them vasodilation, smooth muscle relaxation, sweat secretion, gastrointestinal peristalsis, and pancreatic function. A deficient VIP-innervation of sweat glands was recently described as a possible pathogenic factor in sweating of cystic fibrosis (CF) patients. To investigate a possible role for a defective VIP-gene in cystic fibrosis, we have used a panel of rodent-human hybrid cells, retaining defined complements of human chromosomes to localize the VIP-gene to the human chromosome region 6p21----6qter. As the CF gene was recently mapped to chromosome 7, we conclude that the VIP-gene is not the primary gene defect in this disease.


Subject(s)
Chromosome Mapping , Chromosomes, Human, Pair 6 , Vasoactive Intestinal Peptide/genetics , Animals , Cystic Fibrosis/genetics , DNA Restriction Enzymes , Genetic Markers , Humans , Hybrid Cells , Mice
13.
Eur J Pediatr ; 145(4): 318-20, 1986 Sep.
Article in English | MEDLINE | ID: mdl-3770004

ABSTRACT

A 14-year-old patient with pheochromocytoma is described in whom myocardial ischaemia occurred following hydralazine administration. Possible mechanisms and previously reported paediatric cases are discussed. The need for caution in acute hypotension induction in pheochromocytoma is emphasized.


Subject(s)
Adrenal Gland Neoplasms/complications , Coronary Disease/chemically induced , Hydralazine/adverse effects , Pheochromocytoma/complications , Adolescent , Adrenal Gland Neoplasms/pathology , Cardiomyopathy, Hypertrophic/complications , Cardiomyopathy, Hypertrophic/pathology , Coronary Disease/pathology , Humans , Male , Pheochromocytoma/pathology
15.
Am J Med Genet ; 21(4): 731-5, 1985 Aug.
Article in English | MEDLINE | ID: mdl-2992272

ABSTRACT

Glioblastoma multiforme is a rapidly growing anaplastic primary tumor of the central nervous system. It is frequently associated with neurofibromatosis or other hamartomatous syndromes, and in such kindreds may be found in several generations. We describe a highly inbred family in which glioblastoma multiforme presents in males only as an isolated central nervous system neoplasm on the right side, without evidence of other underlying genetic disease. It is speculated that in this family the tumor develops as the consequence of an autosomal recessive or an X-linked recessive mutation. In addition, the gene for cystic fibrosis segregates in this family and an undefined autosomal recessive malformation syndrome was detected.


Subject(s)
Glioblastoma/genetics , Cystic Fibrosis/genetics , Humans , Inbreeding , Male , Neurofibromatosis 1/complications , Pedigree
16.
Acta Paediatr Scand ; 73(6): 863-7, 1984 Nov.
Article in English | MEDLINE | ID: mdl-6524373

ABSTRACT

A 13-year-old male with prolactin secreting pituitary tumor is described. The unusual features were arrested puberty and growth. Previously reported pediatric patients with prolactinoma are reviewed. The importance of serum prolactin measurement and bromocriptine therapy is emphasized.


Subject(s)
Growth Disorders/etiology , Pituitary Neoplasms/metabolism , Prolactin/metabolism , Puberty, Delayed/etiology , Adenoma, Chromophobe/therapy , Adolescent , Bromocriptine/therapeutic use , Child , Child, Preschool , Combined Modality Therapy , Humans , Male , Pituitary Neoplasms/therapy , Prognosis
18.
Isr J Med Sci ; 20(1): 55-8, 1984 Jan.
Article in English | MEDLINE | ID: mdl-6607909

ABSTRACT

A two-month-old infant was referred to our department because of a short penis (2 X 1.2 cm). No testes were palpable. Acceleration of growth and bone age were observed. Laboratory results showed that serum urea, nitrogen, electrolytes and urinary sodium excretion were all normal. However, levels of serum testosterone (2.1 ng/ml), 17-OH-progesterone (1.8 ng/ml), and 11-deoxycortisol (33 ng/ml) were all high. Urinary excretion of 17-ketosteroids and tetrahydro-s (tetrahydro-pregnane-3 alpha, 17 alpha, 21-triol-20-one) were also very high. Analysis revealed a 46 XX chromosome; laparoscopy revealed normal internal female genitalia. The abnormal concentrations of metabolites were corrected by cortisol acetate treatment. Thus, the diagnosis of virilizing congenital adrenal hyperplasia (11 beta-hydroxylase deficiency) was confirmed. Under our guidance the parents raised the infant as a girl. Reduction clitoroplasty and reconstruction of female external genitalia were performed at the age of 22 months. Early medical, psychological and surgical treatment of children with virilizing congenital adrenal hyperplasia should enable them to become normal adults.


Subject(s)
Adrenal Hyperplasia, Congenital , Adrenal Hyperplasia, Congenital/therapy , Steroid Hydroxylases/deficiency , Adrenal Hyperplasia, Congenital/drug therapy , Adrenal Hyperplasia, Congenital/psychology , Adrenal Hyperplasia, Congenital/surgery , Female , Humans , Hydrocortisone/analogs & derivatives , Hydrocortisone/therapeutic use , Infant
SELECTION OF CITATIONS
SEARCH DETAIL
...